Skip to main content
. 2017 Jan 26;108(1):91–100. doi: 10.1111/cas.13115

Table 4.

Impact of alcohol consumption on survival in 429 patients with head and neck squamous cell carcinoma according to treatment method to primary site

n (%) Overall survival Disease‐specific survival Disease‐free survival
5‐year values (95% CI) HR (95% CI) P‐value 5‐year values (95% CI) HR (95%CI) P‐value 5‐year values (95% CI) HR (95% CI) P‐value
Oral cavity (Op)
Non‐drinker 68 (35) 0.79 (0.65–0.87) 1.00 (Reference) 0.79 (0.65–0.88) 1.00 (Reference) 0.67 (0.54–0.78) 1.00 (Reference)
Light 48 (25) 0.72 (0.54–0.85) 1.92 (0.77–4.76) 0.157 0.73 (0.54–0.85) 1.89 (0.76–4.68) 0.171 0.61 (0.43–0.74) 1.99 (1.02–3.90) 0.043
Moderate 28 (14) 0.57 (0.32–0.76) 3.61 (1.27–10.22) 0.016 0.48 (0.24–0.69) 4.15 (1.55–11.17) 0.005 0.33 (0.14–0.54) 3.17 (1.45–6.94) 0.004
Heavy 46 (24) 0.68 (0.49–0.81) 2.02 (0.72–5.70) 0.184 0.76 (0.58–0.87) 1.36 (0.47–3.96) 0.572 0.53 (0.36–0.68) 1.94 (0.90–4.18) 0.090
Trend P = 0.173 Trend P = 0.429 Trend P = 0.077
Tongue (Op)
Non‐drinker 42 (31) 0.83 (0.62–0.93) 1.00 (Reference) 0.83 (0.63–0.92) 1.00 (Reference) 0.68 (0.50–0.81) 1.00 (Reference)
Light 39 (29) 0.66 (0.43–0.81) 3.20 (0.96–10.60) 0.057 0.66 (0.43–0.81) 3.19 (0.93–10.92) 0.064 0.54 (0.35–0.70) 2.19 (0.99–4.88) 0.054
Moderate 18 (13) 0.43 (0.13–0.70) 11.70 (2.99–45.74) <0.001 0.40 (0.13–0.67) 11.63 (3.04–44.53) <0.001 0.15 (0.01–0.43) 6.36 (2.43–16.65) <0.001
Heavy 34 (25) 0.67 (0.44–0.82) 3.07 (0.76–12.42) 0.117 0.75 (0.54–0.88) 2.04 (0.48–8.58) 0.332 0.51 (0.31–0.68) 2.44 (0.93–6.40) 0.071
Trend P = 0.126 Trend P = 0.345 Trend P = 0.055
Non‐tongue (Op)
Non‐drinker 26 (42) 0.72 (0.50–0.85) 1.00 (Reference) 0.72 (0.49–0.85) 1.00 (Reference) 0.65 (0.43–0.80) 1.00 (Reference)
Light 9 (14) 1.00 1.00 0.88 (0.39–0.98) 0.21 (0.03–1.88) 0.166
Moderate 10 (17) 0.74 (0.29–0.93) 0.09 (0.08–1.07) 0.057 0.59 (0.19–0.85) 0.26 (0.39–2.17) 0.213 0.61 (0.20–0.86) 0.56 (0.94–3.31) 0.522
Heavy 12 (21) 0.71 (0.34–0.90) 0.31 (0.05–1.94) 0.209 0.77 (0.35–0.94) 0.21 (0.03–1.51) 0.123 0.60 (0.22–0.84) 0.58 (0.13–2.54) 0.467
Trend P = 0.322 Trend P = 0.222 Trend P = 0.468
Laryngopharyngeal cancer (oropharyngeal, hypopharyngeal, laryngeal)
Non‐drinker 43 (19) 0.82 (0.60–0.93) 1.00 (Reference) 0.95 (0.81–0.98) 1.00 (Reference) 0.63 (0.42–0.78) 1.00 (Reference)
Light 43 (18) 0.71 (0.49–0.85) 1.43 (0.49–4.19) 0.513 0.73 (0.51–0.86) 2.67 (0.67–10.64) 0.164 0.39 (0.22–0.55) 2.27 (1.08–4.79) 0.030
Moderate 43 (19) 0.69 (0.51–0.81) 1.89 (0.66–5.40) 0.233 0.80 (062–0.90) 2.38 (0.57–9.86) 0.232 0.43 (0.25–0.59) 2.05 (0.96–4.35) 0.062
Heavy 94 (42) 0.54 (0.42–0.65) 2.35 (0.88–6.25) 0.086 0.62 (0.50–0.72) 4.09 (1.11–15.08) 0.034 0.33 (0.23–0.44) 2.35 (1.17–4.69) 0.016
Trend P = 0.054 Trend P = 0.025 Trend P = 0.047
Op
Non‐drinker 14 (17) 0.84 (0.50–0.96) 1.00 (Reference) 0.84 (0.49–0.96) 1.00 (Reference) 0.31 (0.05–0.62) 1.00 (Reference)
Light 14 (17) 0.36 (0.07–0.68) 1.35 (0.23–8.13) 0.737 0.41 (0.07–0.73) 1.05 (0.15–7.32) 0.958 0.21 (0.04–0.46) 1.67 (0.54–5.20) 0.377
Moderate 17 (21) 0.88 (0.59–0.97) 0.60 (0.08–4.33) 0.615 0.93 (0.63–0.99) 0.50 (0.06–4.31) 0.531 0.44 (0.17–0.69) 0.67 (0.20–2.20) 0.507
Heavy 35 (43) 0.48 (0.25–0.68) 1.45 (0.28–7.43) 0.653 0.62 (0.39–0.79) 1.46 (0.28–7.61) 0.648 0.36 (0.16–0.56) 0.98 (0.34–2.82) 0.967
Trend P = 0.592 Trend P = 0.511 Trend P = 0.666
RT
Non‐drinker 29 (20) 0.81 (0.50–0.94) 1.00 (Reference) 1.00 0.78 (0.52–0.91) 1.00 (Reference)
Light 28 (19) 0.89 (0.69–0.96) 0.86 (0.16–4.69) 0.862 0.88 (0.69–0.96) Cannot be estimated§ 0.46 (0.23–0.66) 3.02 (0.94–10.01) 0.067
Moderate 26 (18) 0.59 (0.36–0.76) 2.94 (0.69–12.51) 0.145 0.74 (0.50–0.87) 0.42 (0.21–0.61) 4.37 (1.37–13.93) 0.013
Heavy 59 (41) 0.56 (0.41–0.68) 3.11 (0.76–12.69) 0.113 0.62 (0.48–0.74) 0.31 (0.19–0.44) 5.03 (1.64–15.40) 0.005
Trend P = 0.034 Trend P = 0.009 Trend P = 0.004

Alcohol consumption graded as: light, <23 g ethanol/day; moderate, 23–46 g ethanol/day; and heavy, >46 g ethanol/day. †Adjusted by sex, age, Union for International Cancer Control performance status, stage, primary site, smoker, energy, synchoronous and metachronous, second primary cancer, definitive therapy, and induction chemotherapy. ‡Oral cancer and non‐tongue consist of gingiva, oral floor, and buccal mucosa. §Non‐drinker was no event and hazard ratio (HR) cannot be estimated. CI, confidence interval; Op, surgery; RT, radiotherapy.